Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025

$Plug Power (PLUG.US)$We lowered our rating to HOLD based on earnings growth is still not enough to gain profits. We believe Trump will win the 2024 election, and that will put pressure on Plug Power.  End of 2025 PLUG is estimated to have a loss of ($-0.57) a share. We expect more dilution will also be needed.
PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025
Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant, we see continued prescription growth & expect over 500,000 patients by 2026 which will generate over $2 billion in yearly revenues. Our 2025 yearly earnings estimate is $0.29 to $0.36 per share.  After discussing with Jefferies analyst Dennis Ding we think Esperion has a strong chance of being acquired in the near future, we think Esperion could easily fetch $2 billion, around $10 per share.  
PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025
Recent remarks from Jefferies:
PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
1
Translate
Report
36K Views
Comment
Sign in to post a comment